Recursion Pharmaceuticals, Inc. SEC filings RXRX
Recursion Pharmaceuticals, Inc. has 991 filings in SEC EDGAR's recent list, going back to Apr 2, 2014. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 2, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 2, 2026 (results of operations, officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B5 | Prospectus supplement | Oct 15, 2026 | — |
| 424B5 | Prospectus supplement | Oct 15, 2026 | — |
| S-8 | Employee stock plan registration | Feb 25, 2026 | — |
| 424B5 | Prospectus supplement | Feb 25, 2026 | — |
| 424B7 | Filing | Nov 26, 2025 | — |
| 424B7 | Filing | Aug 29, 2025 | — |
| 424B7 | Filing | Jul 8, 2025 | — |
| 424B7 | Filing | May 9, 2025 | — |
| S-8 | Employee stock plan registration | May 5, 2025 | — |
| 424B5 | Prospectus supplement | Feb 28, 2025 | — |
| S-3ASR | Automatic shelf registration | Feb 12, 2025 | — |
| 424B7 | Filing | Dec 17, 2024 | — |
| S-8 | Employee stock plan registration | Nov 20, 2024 | — |
| 424B5 | Prospectus supplement | Jun 27, 2024 | — |
| 424B5 | Prospectus supplement | Jun 26, 2024 | — |
| S-8 | Employee stock plan registration | May 10, 2024 | — |
| 424B7 | Filing | Dec 15, 2023 | — |
| 424B5 | Prospectus supplement | Aug 8, 2023 | — |
| 424B7 | Prospectus [rule 424(b)(7)] | Aug 8, 2023 | — |
| 424B5 | Prospectus supplement | Jun 9, 2023 | — |
| S-8 | Employee stock plan registration | May 30, 2023 | — |
| S-3ASR | Automatic shelf registration | May 30, 2023 | — |
| S-8 | Employee stock plan registration | May 18, 2023 | — |
| S-8 | Employee stock plan registration | May 8, 2023 | — |
| 424B3 | Prospectus | Oct 28, 2022 | — |
| S-8 | Employee stock plan registration | May 10, 2022 | — |
| S-3ASR | Automatic shelf registration | May 10, 2022 | — |
| S-8 | Employee stock plan registration | Apr 16, 2021 | — |
| 424B4 | Prospectus | Apr 16, 2021 | — |
| S-1MEF | Filing | Apr 15, 2021 | — |
| S-1/A | Amended registration statement | Apr 15, 2021 | — |
| S-1/A | Amended registration statement | Apr 12, 2021 | — |
| S-1 | Registration statement | Mar 22, 2021 | — |
Showing 33 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- RXRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Salt Lake City, UT
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1601830
- Former names
- Recursion Pharmaceuticals, LLC (until Dec 4, 2015)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.